Overall survivals at 2 years of patients with advanced disease; 48 patients received cyclosporine/methotrexate, 41.7% (◊) and 68 patients received tacrolimus/methotrexate, 24.8% (□); absolute difference = 16.9%, 95% CI = −34.3 to 0.4 (P = .006, Wilcoxon).